We are live on
!
Find out more
ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
1-Year Est. Return
7.38%
This Fund
S&P 500
This Quarter
Est. Return
+1.18%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$254M
AUM Growth
+$704K
(+0.28%)
Cap. Flow
+$4.85M
Cap. Flow
% of AUM
1.91%
Top 10 Holdings %
Top 10 Hldgs %
43.68%
Holding
90
New
20
Increased
18
Reduced
11
Closed
40
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PRAH
PRA Health Sciences, Inc.
PRAH
|
+$9.28M |
| 2 |
Takeda Pharmaceutical
TAK
|
+$9.02M |
| 3 |
SIEN
Sientra, Inc.
SIEN
|
+$8.62M |
| 4 |
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
|
+$8.05M |
| 5 |
Humana
HUM
|
+$7.05M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Icon
ICLR
|
+$13.8M |
| 2 |
Gilead Sciences
GILD
|
+$10.1M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$9.55M |
| 4 |
VCRA
VOCERA COMMUNICATIONS, INC.
VCRA
|
+$5.99M |
| 5 |
Evolent Health
EVH
|
+$5.27M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 77.04% |
| 2 | Technology | 6.14% |
| 3 | Industrials | 4.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Takeda Pharmaceutical
TAK
$54.6B
| $16.5M | 6.51% |
932,967
+495,531
| +113% | +$9.02M |
|
2
Labcorp
LH
$25B
| $14.3M | 5.65% |
96,496
+44,268
| +85% | +$6.18M |
|
3
Zimmer Biomet
ZBH
$18.2B
| $12.9M | 5.09% |
112,921
+33,316
| +42% | +$3.9M |
|
|
WMGI
4
DELISTED
Wright Medical Group Inc
WMGI
| $11.1M | 4.37% |
371,979
+124,562
| +50% | +$3.8M |
|
|
RCM
5
DELISTED
R1 RCM Inc. Common Stock
RCM
| $10.5M | 4.12% |
830,809
+80,433
| +11% | +$908K |
|
6
Cigna
CI
$73.7B
| $9.7M | 3.83% |
61,590
-5,407
| -8% | -$847K |
|
|
PRAH
7
DELISTED
PRA Health Sciences, Inc.
PRAH
| $9.64M | 3.8% |
+97,200
| New | +$9.28M |
|
|
IIN
8
DELISTED
IntriCon Corporation
IIN
| $9.11M | 3.59% |
389,795
-162,662
| -29% | -$4.07M |
|
|
OXFD
9
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $8.66M | 3.41% |
629,236
+526,643
| +513% | +$8.05M |
|
10
iRhythm Holdings
IRTC
$3.85B
| $8.18M | 3.23% |
103,448
+53,115
| +106% | +$3.87M |
|
|
SIEN
11
DELISTED
Sientra, Inc.
SIEN
| $7.92M | 3.12% |
128,586
+119,749
| +1,355% | +$8.62M |
|
|
12
Humana
HUM
$43.7B
| $7.38M | 2.91% |
+27,797
| New | +$7.05M |
|
13
Encompass Health
EHC
$11B
| $7.27M | 2.87% |
+144,305
| New | +$7M |
|
|
AVDR
14
DELISTED
Avedro, Inc Common Stock
AVDR
| $7.03M | 2.77% |
357,942
-84,047
| -19% | -$1.35M |
|
15
AtriCure
ATRC
$1.92B
| $6.54M | 2.58% |
219,038
-47,539
| -18% | -$1.39M |
|
|
VCRA
16
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
| $6.48M | 2.55% |
203,000
-187,887
| -48% | -$5.99M |
|
17
AbbVie
ABBV
$443B
| $6.47M | 2.55% |
89,008
+67,334
| +311% | +$5.29M |
|
18
Cencora
COR
$60.6B
| $6.27M | 2.47% |
73,503
-15,033
| -17% | -$1.19M |
|
|
XENT
19
DELISTED
Intersect ENT, Inc
XENT
| $6.16M | 2.43% |
270,561
+205,004
| +313% | +$5.53M |
|
20
HCA Healthcare
HCA
$87.2B
| $5.9M | 2.32% |
43,623
-16,452
| -27% | -$2.08M |
|
21
Sanofi
SNY
$103B
| $5.22M | 2.06% |
+120,614
| New | +$5.13M |
|
22
AstraZeneca
AZN
$263B
| $5.15M | 2.03% |
+62,430
| New | +$4.9M |
|
23
Dentsply Sirona
XRAY
$2.68B
| $4.83M | 1.91% |
82,813
+53,825
| +186% | +$2.89M |
|
24
Iovance Biotherapeutics
IOVA
$1.82B
| $4.25M | 1.67% |
+173,238
| New | +$2.61M |
|
|
NVRO
25
DELISTED
NEVRO CORP.
NVRO
| $4.11M | 1.62% |
+63,394
| New | +$3.95M |
|
Similar funds
VAFP
CA
SCM
FWM
TOPU
CCMU
TGI
HSCU
Endurant Capital Management's Q2 2019 Portfolio in Review
As of Q2 2019, Endurant Capital Management held 90 positions worth $254M, up 0.28% from $253M the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Endurant Capital Management's Q2 2019 filing shows 20 new, 18 increased, 11 reduced and 40 closed positions. Its largest new stake was PRA Health Sciences, Inc.: 97,200 shares worth $9.64M. The largest sale was Icon, an estimated $13.8M.
By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 74% a quarter earlier, followed by Technology and Industrials.
- Endurant Capital Management's largest Q2 2019 buy was PRA Health Sciences, Inc.: 97,200 shares worth $9.64M.
- Endurant Capital Management added most to Takeda Pharmaceutical in Q2 2019, an estimated $9.02M increase.
- Endurant Capital Management's biggest Q2 2019 reduction was Bristol-Myers Squibb, cutting an estimated $9.55M.
- Endurant Capital Management fully exited Icon in Q2 2019, selling an estimated $13.8M.
- Endurant Capital Management's ten largest holdings make up 44% of its $254M portfolio in Q2 2019.
- Endurant Capital Management opened 20 new positions and closed 40 in Q2 2019.
- Endurant Capital Management's portfolio value rose 0.28% quarter-over-quarter to $254M.
Based on Endurant Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.